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DYSBIOSIS IN INFLAMMATORY BOWEL DISEASE PROMOTES 
CLOSTRIDIUM DIFFICILE COLONIZATION 
NICHOLAS HAFFTEN 
ABSTRACT 
 Research into the gut microbiome has revealed the widespread influence that 
microbial species have on their host. Host genetics and environmental factors influence 
the abundance and diversity of the bacterial species living within the gastrointestinal 
tract. When the normal composition of the gut microbiota is altered, a dysbiotic state 
incurs. Inflammatory bowel disease (IBD) is a chronic/relapsing inflammatory disorder 
of the intestinal mucosa, which is characterized by a state of dysbiosis. Despite the large 
amount of information studying the role dysbiosis has in the pathogenesis of IBD, it is 
not clear how the altered microbial composition of the gut in IBD patients leads to 
susceptibility to enteric pathogens such as Clostridium difficile. This study aims to 
highlight the features of the gastrointestinal tract that are modified as a result of dysbiosis 
in the IBD population, and how these features facilitate colonization by C. difficile and 
symptom development. Review of the available literature demonstrated that the depletion 
of Clostridial cluster XIVa in IBD-associated dysbiosis alters bile acid metabolism and 
butyrate fermentation in the colon, ultimately promoting germination of C. difficile 
spores and weakening the gut’s immune response against toxin-mediated inflammation. 
From continued research into the gut microbiota, more will be understood of how these 
microbial organisms influence human health and disease. 
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INTRODUCTION 
 
The human microbiome is characterized by the microorganisms that live in or on 
the human body. It is estimated that 100 trillion microbes reside in the human body, 
correlating to 10 times the number of human cells, and 100 times the number of gene 
products (Ley et al. 2006). Historically, science has focused on identifying pathological 
bacterial species and their involvement in disease. However, with the advent of high 
throughput technology such as 16S rRNA and whole genome shotgun (WGS) 
sequencing, there has been a vast increase in studies attempting to identify the 
commensal and symbiotic bacterial species living within the human body (NIH HMP 
Working Group et al. 2009).  
 The growing interest in the human microbiome spurred the initiation of the 
Human Microbiome Project (HMP). The overall goal of this NIH sponsored, 5-year, 
$157 million dollar project is to identify the residential bacterial species of the human 
body and determine their role in human health and disease (NIH HMP Working Group et 
al. 2009). In its jumpstart phase, initiated in 2007 and completed in 2012, the HMP aimed 
to generate reference databases representative of the human microbiome and to develop 
the necessary computational tools to analyze such data (National Institutes of Health, 
2015). A total of 4,788 samples were collected across 15-18 body sites (15 for male and 
18 for female including vaginal sites) from “healthy” participants ranging in ages 18-40 
years old (Human Microbiome Project Consortium 2012b). “Health” was determined 
through clinical screening criteria set forth by the consortium. Each participant gave 1-3 
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samples, which were collected by swabs with the exception of stool, which was collected 
by the participant using a collection kit. As of early 2015, the HMP has sequenced over 
1,300 genomes related to the human microbiome (NIH HMP Working Group et al. 2009; 
Human Microbiome Consortium 2012a; Human Microbiome Project - DACC HMP 
Reference Genomes 2015).  
 The HMP is currently in its second phase and has 3,024 reference genome and 
1,265 metagenomics projects in progress (Human Microbiome Project - DACC HMP 
Data Catalog 2015; National Institute of Health 2015). With plans to complete this phase 
in late 2015, the HMP hopes to have compiled databases that will facilitate the 
understanding of what constitutes the “core microbiome”, a term used to describe the 
bacteria normal to the human body (NIH HMP Working Group et al. 2009; National 
Institute of Health, 2015). Ultimately, by knowing what constitutes a “healthy” 
microbiome, physicians and scientists will be able to identify an “unhealthy” 
microbiome, and hopefully develop methods to manipulate its status to improve human 
health.  
1.1 Sequencing Methods 
16S rRNA analysis and other sequencing methods, such as whole genome shotgun 
(WGS) sequencing, have facilitated the large growth in classification of unculturable 
microorganisms. Culture-based experiments were heavily relied upon before the 
development of molecular techniques, which greatly limited the study of microbial 
communities, as approximately 80% of bacterial are unculturable (Hugenholtz, 2002; 
Connon and Giovannoni, 2002). The development of 16S rRNA analysis resolved this 
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issue as this provided a way to analyze the genomes of these unculturable bacteria 
(Woese and Fox 1977; Woese 1982). The analysis of 16S rRNA is utilized since these 
sequences are sufficiently conserved in bacteria and yet varied enough to distinguish 
between bacterial species and other microbes such as Archaea (Weng et al. 2006). 16S 
rRNA analysis proceeds by extracting bulk DNA from the environment and then 
amplifying the 16S rRNA sequences using highly conserved PCR primers (Hugenholtz 
2002) (Figure 1). The amplified sequences (typically 1,500 base pairs in length) are then 
cloned using vectors, clustered based on similarity, and compared to genomic libraries for 
phylogenetic classification (Weng et al. 2006). Once identified, these sequences give 
evidence to the microbial composition of the sample, both in terms of relative abundance 
and membership. By identifying the relative abundances of the bacteria present, the 
impact that particular species may have on the environment can be discerned.  
 
Figure 1. The Process of 16S rRNA analysis 
The extracted bulk DNA is amplified using site-specific primers for the 16S rRNA 
genomes. The products are then cloned and compared to genomic databases allowing 
classification of the species. Adapted from Weng et al. 2006. 
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While the 16S rRNA analysis is beneficial for the identification of species, it does 
not describe the functions of these microorganisms. To determine the functions of the 
bacteria in an environment, WGS sequencing is used (Tyson et al. 2004; Venter et al. 
2004). WGS assesses the “metagenome” or collective genomic content of the microbial 
community within an environment (Handelsman et al. 1998). Instead of amplifying the 
genomic sequences as in 16S rRNA analysis, the DNA extracted from the environment is 
randomly cut, which creates many fragmented pieces of DNA (Figure 2) (Riesenfeld et 
al. 2004). These fragments are then cloned into vectors and subjected to functional-driven 
analysis and/or sequence-driven analysis (Handelsman, 2004). Functional-driven analysis 
entails transforming the clones into a host bacterium in order to determine the function of 
the cloned sequences. This process is helpful in identifying the functions of the 
metagenome, however, it is difficult to know from which bacteria the expressed gene 
product originated (Handelsman, 2004). Sequence-driven analysis provides insight into 
the types of bacteria contributing genomic content to the metagenome by looking for 
phylogenetic markers, or “anchors”, in the DNA flanking the cloned sequence 
(Handelsman, 2004).  Researchers are then able to link gene products to the bacteria of 
origin (Handelsman, 2004). The utilization of sequencing methods such as 16S rRNA 
analysis and WGS has provided tools to studying the bacteria that live within or on the 
human body.  
	   5	  
 
Figure 2. The Process of Whole Genome Shotgun Sequencing 
Schematic representation of the construction of metagenomic libraries obtained from 
WGS. After creation of a metagenomic library, these sequences are subjected to either 
functional-driven or sequence-driven analysis in order to determine the function or 
species of origin, respectively. Adapted from Handelsman, 2004.   
 
1.2 The Human Microbiome  
 The human microbiome is a complex collection of microbial ecosystems. Based 
on the areas sampled in the HMP, the human microbiome is divided into 5 main 
microbial habitats: oral cavity, nasal cavity, urogenital tract, skin, and GI tract (Figure 3) 
(Human Microbiome Project Consortium 2012b). The microbial composition of each 
area is assessed by the diversity of the genomic data obtained at each site. The variation 
in diversity exhibited by the different body habitats demonstrate that each site differs in 
its microbial composition in comparison to other sites (Figure 4) (Human Microbiome 
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Project Consortium 2012b). Additionally, the diversity of species observed varies at each 
site. For example, the oral cavity and GI tract exhibit a much more diverse bacterial 
composition, whereas the vagina harbors a relatively low diversity of bacteria (Costello et 
al. 2009; Human Microbiome Project Consortium 2012b).  
 
Figure 3. HMP sample sites  
Multiple sites were sampled from the oral cavity, skin, and vagina. Only stool and 
anterior nares samples were obtained from gut and respiratory tract, respectively. 
Appended from “Human Microbiome Project DACC - Microbiome Analyses,” 2015.  
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Figure 4. Clustering of bacterial composition based on microbial habitat 
Principal coordinate plot demonstrates distinct variation patterns between body areas. 
Gastrointestinal, oral, and urogenital samples are distinguished from all areas. Skin and 
nasal samples overlap and are separate. Adapted from Human Microbiome Project 
Consortium 2012b.  
 
 The variations in microbial composition differ depending on both the body habitat 
and the individual (Human Microbiome Project Consortium 2012b). The diversity 
observed in the different locations of one subject is defined as the alpha diversity and the 
diversity observed at one location, but between subjects is termed the beta diversity. 
Thus, the alpha diversity would describe species variety of the skin microbiota of Person 
A, while beta diversity would compare the skin microbiota between Person A and Person 
B. The alpha and beta diversities of the human microbiome both vary in every major 
body area (Figure 5) (Human Microbiome Project Consortium 2012b). For example, the 
oral cavity demonstrates high alpha diversity and low beta diversity. This means that 
although the oral cavity was species rich, a majority of these species were conserved 
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across individuals. On the other hand, samples taken from the vagina of healthy, non-
pregnant women demonstrated both low alpha and beta diversities, correlating to both 
low species richness and low inter-individual variability.  
 
Figure 5. Variation of alpha and beta diversities between niches of the human 
microbiome 
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a. Alpha diversity within subjects, grouped by individual niche, and measured using the 
relative inverse Simpson index of genus-level phylotypes (cyan), 16S rRNA gene OTUs 
(blue), shotgun metagenomic reads matched to reference genomes (orange), functional 
modules (dark orange), and enzyme families (yellow). The mouth and vagina 
demonstrate high and low alpha diversity, respectively. The other body niches generally 
display intermediate alpha diversity. Individual variation was often greater than variation 
between body habitats. b. Bray-Curtis beta diversity among subjects, grouped by niche, 
and measured in similar colors as (a). The skin demonstrates the greatest beta diversity. 
The mouth and vagina are relatively stable. The alpha and beta diversity are not directly 
comparable, though the variation observed in (a) exhibited a greater range than the 
variation observed in (b). Adapted from Human Microbiome Project Consortium 2012b. 
 
 Each body habitat of the human microbiome is dominated by one or several phyla 
(Figure 6a) (Human Microbiome Project Consortium 2012b). The abundance of the 
dominant clade varies depending on the individual, representing on average 17-84% of 
the total genera. However, in some individuals the typical dominant clade may represent 
0% or 100% of the genera present. The less abundant taxa are highly diverse depending 
on the habitat and individual. For example, in the oral cavity the dominant genus was 
Streptococcus, but the next most abundant genus varies depending on the location within 
the oral cavity (buccal mucosa, supragingival plaque, and tongue dorsum) (Segata et al. 
2012). 
 The variation in the microbial composition observed across individuals contrasts 
with the relative stability of the “core” metabolic functions across habitats (Figure 6b) 
(Human Microbiome Project Consortium 2012b). Turnbaugh et al. 2009 demonstrated 
that the assemblages of microbial species vary widely from person to person, yet the 
primary metabolic and biochemical profiles are conserved. This suggests that these 
“core” functions are not specific to particular clades, but are instead shared across a 
multitude of species. It is not clear how core functionality is determined given the highly 
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variable structure of the gut microbiota (Turnbaugh et al. 2009). Interestingly, low 
abundance metabolic pathways are highly conserved (Human Microbiome Project 
Consortium 2012b). For example, spermidine biosynthesis, methionine degradation, and 
hydrogen sulfide production are all active at low levels in the GI tract, but are present in 
>92% of subjects (Human Microbiome Project Consortium 2012b). It is speculated that 
many of these lowly expressed, highly conserved pathways are yet to be discovered and 
harbor the uncharacterized functions observed within the different body habitats.  
Figure 6.  Phyla distribution varies across subjects and sample sites while metabolic 
pathways remain stable  
Vertical bars represent microbiome samples obtained from the seven niches with both 
shotgun and 16S rRNA data; bars indicate relative abundances colored by microbial 
phyla (a) and metabolic modules (b). One or several phyla typically dominate the niche. 
In contrast, metabolic pathways are stable across subjects and niches. Adapted from 
Human Microbiome Project Consortium 2012b. 
 
1.3 The Gut Microbiome 
The GI tract has received the most attention from the HMP, making up 25.5% 
(772/3,024) and 25% (253/1,265) of the ongoing reference genome and metagenomic 
projects, respectively (Human Microbiome Project - DACC HMP Data Catalog 2015). It 
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is estimated that approximately 1013-1014 microbial cells reside in the human gut, the 
most of any human body habitat (Human Microbiome Project Consortium 2012a). The 
microbial composition of the human gut varies widely between individuals on account of 
multiple factors such as race, diet, and medications (Human Microbiome Project 
Consortium 2012b). The relationship the body has with its microbiota ranges from 
gaining physiological benefits to receiving unwanted inflammation (Kaiko and 
Stappanbeck 2014). The amount of ongoing research in the gut microbiome reflects its 
overall complexity and enormity.  
 The initial colonization of the human gut begins at birth. Until recently, the gut 
microbiome was thought to be a completely nonexistent at birth (Clemente et al. 2012). 
However, samples from umbilical cord blood and meconium have demonstrated the 
presence of bacteria in utero (Jimenez et al. 2008). It is still widely accepted that the 
primary colonization event occurs during birth when the neonate is exposed to a variety 
of new bacterial species depending on the route of delivery (Adlerberth & Wold 2009; 
Dominguez-Bello et al. 2010). For example, neonates born via cesarean section exhibit 
early colonization by species resident to the skin, while neonates born via vaginal 
delivery are typically colonized by bacteria resident to the mother’s vagina (Dominguez-
Bello et al. 2010).  
 Following birth, the gut is low in both diversity of species and number of 
microbial cells (Clemente et al. 2012). Initially, the human gut is host to facultative 
anaerobes, such as Proteobacteria, given the highly oxidative environment (Sommer and 
Backhed 2013). These early aerotolerant species are eventually replaced with anaerobes 
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as the gut decreases in environmental oxygen (Palmer et al. 2007). With exposure to solid 
foods and other agents such as antibiotics, the microbiome grows and widely fluctuates in 
composition (Koenig et al. 2011). By 11 months old, an infant’s microbiome contains 
microbial species that can be very different than the mother’s (Vaishampayan et al. 
2010). At 12 months, the gut microbiome begins to stabilize and at 2.5 years it fully 
resembles its adult profile (Palmer et al. 2007; Koenig et al. 2011).  
In adulthood, the density of microbial cells increases with progression from the 
stomach to the colon, with the colon harboring 70% of the microbial content of the entire 
GI tract (Eckburg et al. 2005; Gill et al. 2006; Ley et al. 2006). The adult gut microbiome 
is comprised mainly of bacteria, though Archaea, microbial Eukaryotes, and viruses also 
exist (Haynes and Rowher 2011; Clemente et al. 2012). Anaerobic species of bacteria 
outnumber aerobic and facultative species 100:1 and 1,000:1, respectively (Clemente et 
al. 2012). In general, membership at the phylum level is stable over time with 
Bacteroidetes and Firmicutes dominating the gut, and Actinobacteria, Proteobacteria, and 
Verrumicrobia present in comparatively smaller numbers (Figure 7) (Qin et al. 2010; 
Human Microbiome Project Consortium 2012b). However, the microbial composition at 
the genera level continually evolves in response to a variety of factors (Eckburg et al. 
2005; Human Microbiome Project Consortium 2012b).  
The microbial composition varies between and within each histologically distinct 
area of the GI tract. This is termed longitudinal variation and latitudinal variation, 
respectively. Longitudinal variation exists due to the differences within the gut 
environment (e.g. substrate availability, pH, host secretions, flow rate) (Human 
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Microbiome Project Consortium 2012b; Flint et al. 2012). For example, the 
Lachnospiraceae class of Firmicutes and Bacteroidetes dominate the colon due to slow 
flow rates, mildly acidic pH, and their ability to ferment indigestible glycans (Frank et al. 
2007; Human Microbiome Project Consortium 2012b; Lee et al. 2013; Ng et al. 2013). 
On the other hand, in the small intestine, the Bacilli class of Firmicutes and 
Actinobacteria dominate due to the higher oxygen concentrations, availability of short 
chain carbohydrates and amino acids, lower pH due to bile acid secretions, and faster 
flow rates (Booijink et al. 2010; Zoetendal et al. 2012; Human Microbiome Project 
Consortium 2012b).  
Latitudinal variation results primarily from the mucus layer that lines the 
intestines, which creates both a physical and chemical barrier to its inhabitants. Via 
fluorescence in situ hybridization (FISH) experiments, Swidsinski et al. 2005 
demonstrated that only particular species of bacteria were able to colonize the mucus 
layer. For example, species from the genera Clostridium, Enterococcus, and 
Lactobacillus were found in both feces and the mucus layer, however, species from other 
genera such as Bacteroides, Bifidobacterium, Streptococcus, and Ruminococcus were 
only found in feces. These findings suggest that sampling the stool is inadequate in 
determining the microbiota of the colonic mucosa, and vice versa. However, 16S rRNA 
analysis of the bacterial genomes in the colonic mucosa demonstrated similar proportions 
of bacterial sequences as ones obtained from stool (Eckburg et al. 2005; Wang et al. 
2005; Durban et al. 2010; Hong et al. 2011; Stearns et al. 2011; Human Microbiome 
Project Consortium 2012b). For example, the Firmicutes to Bacteroidetes ratio 
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determined from mucosal samples ranged from 1.27 (50.9% to 40.2%) to 4.62 (76.2% to 
16.5%), which were well within the ratios of stool samples displayed in Figure 5 
(Eckburg et al. 2005; Wang et al. 2005; Durban et al. 2010; Hong et al. 2011; Stearns et 
al. 2011; Human Microbiome Project Consortium 2012b). At the time this paper is 
written, it appears that both types of samples are adequate in determining the bacterial 
composition of the gut at the phylum level, though discrepancies arise when analyzing at 
the genera level. It will become more important to discern between the types of samples 
and how they relate to metagenomes, as more is understood of how particular species 
impact the gut microbiome.  
As people age, there are general differences in the microbial composition of the 
gut in comparison to younger adults. Claesson et al. 2011 compared the microbial 
composition of participants >65 years of age to participants between 18-58 years of age. 
This study found that the elder group demonstrated a shift in the Bacteroidetes:Firmicutes 
ratio, as well as altered levels of Clostridial groups (Figure 7) (Claesson et al. 2011). The 
authors proposed that these changes might result from increased usage of oral 
medications taken to treat various morbidities associated with advanced age. As the gut 
microbiota take part in metabolism of various drugs including acetaminophen, digoxin, 
and lovastatin, it is not unforeseeable that these drugs exert effects on the bacterial 
populations (Saad et al. 2012; Yoo et al. 2014). 
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Figure 7. Representation of the gut microflora in adults and the elderly   
The core fecal microbiota of elderly subjects (>65 years old) at the level of phylum, 
genera, and Clostridial cluster compared to the core microbiota of nine younger adult 
controls and other documented core microbiota. Elderly subjects demonstrate a higher 
Bacteroidetes:Firmicutes ratio and altered genera/Clostridial cluster distribution than 
younger adults. Adapted from Claesson et al. 2011.  
 
1.4 The Immune System and Gut Microbiota 
  Over the past millions of years, mammals and their microbiota have evolved a 
symbiotic relationship (Ley et al. 2008). However, given the proximity of the microbes to 
the intestinal epithelium, there is always risk unwanted inflammation. The host immune 
system aids in the development of the microbial community and continually monitors its 
composition (McFall-Ngai, 2007; Chow et al. 2010; Kawamoto et al. 2014). The 
development of the gut microbiota in tandem with the gut immune system is imperative 
to gut homeostasis; failure to develop properly results in hypersensitivity or autoimmune 
disorders (Loftus, 2004; Halfvarson et al. 2006; Wen et al. 2008; Lee and Mazamanian 
2010). 
  The mucus layer, a component of the gut’s innate immune system, is the 
predominant barrier between host tissue and residential microbiota (Johansson et al. 
2011). As discussed above, the mucus layer partitions the gut microbiota since only 
	   16	  
particular species are able to colonize the mucosa (Swidsinski et al. 2005). The mucus 
layer is composed of an inner and outer layer made of sheets of mucin secreted by Goblet 
cells (Johansson et al. 2008; Johansson et al. 2011). Mucin 2 (MUC2), a highly 
glycosylated protein, is the predominant component of the mucus layer and provides 
antimicrobial protection (Johansson et al. 2011). For example, Muc2-deficient mice are 
shown to be more susceptible to spontaneous and chemically induced colitis (An et al. 
2007; Petersson et al. 2011; Fu et al. 2011). Because of the scaffolding of mucin sheets, 
bacteria are unable to maneuver within the inner layer of the mucosa, though they can 
occupy the outer layer (Johansson et al. 2008; Juge, 2012; Ambort et al. 2012). There is 
evidence that the gut microbiota influences the structure of the mucus layer. In 
comparison to conventionally housed mice, germ-free mice displayed fewer Goblet cells 
on average, which corresponded to a thinner mucus layer and altered mucin content 
(Sharma et al. 1995). However, by introducing bacterial cell wall components such as 
peptidoglycan and lipopolysaccharide (LPS) in the germ-free mice, the mucus regained 
normal characteristics (Petersson et al. 2011). This suggests that the microbiota are 
closely involved in the development gut epithelium and mucus layer, though details of 
this process are still unclear (Peterson et al. 2011).  
To a similar effect, antimicrobial peptide (AMP) secretion is stimulated by direct 
contact with microbial cells. These innate effector molecules are considered “natural” 
antibiotics and are produced by almost every plant and animal (Zasloff, 2002). AMPs 
vary by type, body niche, secretory cell, and cellular target (Table 1). In the gut, AMPs 
are primarily produced and secreted in the crypts of Lieberkuhn by Paneth cells, though 
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intestinal epithelial cells and some immune cells also participate along the length of the 
GI tract (Gallo and Hooper, 2012). The secretion of AMPs is stimulated by the gut 
microbiota. Studies using a murine model demonstrated that germ-free mice displayed 
significantly lower levels of β-defensins and RNases in comparison to their 
conventionally raised littermates, suggesting the presence of the microbiota is the trigger 
for AMP release (Hooper et al. 2003). Several molecular pathways govern AMP 
expression. For example, Reg3-γ (C-type lectin) expression is triggered through a toll-
like receptor (TLR) dependent manner whereas other AMPs are dependent on activation 
of intracellular nucleotide binding domains (NODs) (Brandl et al. 2006; Petnicki-Ocwieja 
et al. 2009). NODs and TLRs are activated by a variety of stimuli including microbial 
antigens, such as cell wall components and nucleic acid, as well as non-microbial 
antigens such as food particles (Gallo and Hooper, 2012). This suggests that the local 
microbiota and gut environment play a pivotal role in activating of these molecular 
pathways, impacting the secretion of AMPs and gut homeostasis.    
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Table 1. Major antimicrobial peptides of the skin and intestines 
ANG4, angiogenin 4; BD, β-defensin; CRAMP, cathelin-related antimicrobial peptide; 
DEFA, α-defensin; GAL, galectin; HIP/PAP, hepatointestinal pancreatic/pancreatitis-
associated protein; NA, not applicable; PGLYRP, peptidoglycan recognition protein; 
REG3γ, regenerating islet-derived protein 3γ; RNase, ribonuclease. Adapted from Gallo 
and Hooper, 2012. 
 
The adaptive immune system is also linked to the gut microbiota. IgA is the 
principal component of the adaptive immune system of the gut mucosa (Gutzeit et al. 
2014). IgA is transcytosed across the intestinal epithelium and secreted into the intestinal 
lumen, where it opsonizes bacteria for destruction. The gut microbiota influence the 
secretion of IgA in the intestines. For example, germ-free mice display marked decreases 
in IgA secretion compared to conventionally raised mice (Moreau et al. 1978). This 
immunological defect is reversible when the germ-free mice are colonized with bacteria 
from a normal mouse colon, suggesting that the gut microbiota are responsible for 
inducing IgA secretion in the intestines (Hapfelmeier et al. 2010). IgA secretion is 
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initiated by the migration of activated dendritic cells from the intestinal epithelium to 
secondary lymphoid structures, where antigens are presented to naïve B cells for 
activation and class switching (Macpherson and Uhr 2004; Wesemann et a. 2013). 
Through this mechanism, the gut microbiota “educate” the adaptive immune system to 
target luminal antigens, increasing IgA specificity (Wesemann et al. 2013).   
The secretion of IgA affects the density and diversity of the gut microbiota. By 
opsonizing bacteria within the intestinal lumen, IgA aids in the elimination of microbial 
cells, thus preventing overgrowth. Without IgA secretion into the gut, there is an 
increased density of bacterial cells in the lumen, increased translocation of select species 
across the intestinal epithelium, and increased numbers of bacteria draining from the 
mesenteric lymph nodes (Johansen et al. 1999; Wei et al. 2011). The diversification of 
the gut microbiota by the IgA secretion is carried out in a positive feedback manner. 
Kawamoto et al. 2014 demonstrated that the diversity of the gut microbiota is dependent 
on the variety of IgA repertoires of intestinal B cells. In this study, Foxp3+ regulatory T 
cells (Tregs) were transferred into T cell deficient mice, which expanded the IgA 
specificity of B cells in Peyer’s patches (Figure 8). This in turn increased the diversity of 
the gut microbiota in terms of representative species, particularly in the Firmicutes 
phylum, which induced Treg differentiation. This positive feedback loop illustrates the 
symbiotic relationship between the host and gut microbiota and also the critical role the 
adaptive immune system has in maintaining gut homeostasis. Alterations to either the gut 
microbiota or the immune system can have negative effects on the host, as is in the case 
of inflammatory bowel disease (IBD).  
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Figure 8. Diversified community of gut microbiota expand IgA repertoire in 
regulatory loop mechanism 
IgA secretion into the lumen of the intestines modulates the diversity of the gut 
microbiota. Increased diversity and expansion of Firmicutes results in Treg (Foxp3+) 
differentiation. Migration of the differentiated Tregs to germinal centers induces IgA 
selection, generating a pool of plasma cells with a diverse IgA specificity. Adapted from 
Kawamoto et al. 2014.  
 
1.5 Inflammatory Bowel Disease and the Gut Microbiome 
 Inflammatory bowel disease is a chronic relapsing inflammatory condition of the 
intestinal mucosa, which is characterized by disruption of the normal gut homeostasis. 
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The two major forms of IBD, Crohn’s disease (CD) and ulcerative colitis (UC), differ in 
clinical manifestations and symptoms (Targan et al. 2003). CD affects the entire length of 
the GI tract and patients generally present with fatigue, diarrhea (no bloody stools), fever, 
diffuse abdominal pain, and/or weight loss (Targan et al. 2003). Divergently, UC 
typically affects only the colon and patients present with rectal bleeding, tenesmus, 
mucousy stools, lower abdominal pain, and/or frequent stooling (Targan et al. 2003).  
The incidence of IBD is increasing worldwide and varies depending on region 
(Desail and Gupte 2005; Zheng et al. 2005; Molodecky et al. 2012;). It is estimated that 
over 5 million individuals are affected by IBD including 1.6 million from the United 
States and 3 million from Europe (Burisch et al. 2013). Changes in overall diet and 
hygiene correlate with the increased prevalence of IBD (Moledecky et al. 2012). For 
example, in comparison to the general population of North American and Western 
European countries, immigrants moving from developing countries to these modernized 
countries display a higher incidence of IBD (Probert et al. 1992; Barreiro-de Acosta et al. 
2011). With yearly expenditures per patient costing more than diabetes, stroke, coronary 
artery disease, chronic obstructive pulmonary disease, or multiple sclerosis, it is clear that 
the rising prevalence of IBD is a major burden on health care costs (Kappelman et al. 
2007; Gunnarsson et al. 2012).  
The definitive etiology of IBD is unclear, though the current pathological model 
describes a “multihit” phenomenon that precipitates the disease (Figure 9) (Bringiotti et 
al. 2014). Factors contributing to the onset and pathology of IBD include genetic, 
environmental, and immunological triggers (Targan et al. 2003). Large-scale genetic 
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studies have identified 163 loci related to gut homeostasis and IBD susceptibility (Khor 
et al. 2011; Jostins et al. 2012). Nod2, a gene coding for a type of NOD, was the first 
gene implicated in host susceptibility to IBD and is still considered to be the strongest 
genetic determinant, though there are now a handful of genes identified as known 
markers for IBD (Hugot et al. 2001; McCauley and Abreu, 2012; Connelly et al. 2015). 
Most genetic markers for IBD are mutations in proteins linked to the immune system, 
which influence the state of the gut microbiome. For example, NOD2 is a protein 
expressed on several innate immune system cells including intestinal epithelial cells, 
dendritic cells, and Paneth cells (McCauley and Abreu, 2012). NOD2 detects muramyl 
dipeptide (a component of LPS) and triggers downstream activation pathways such as 
mitogen-activated protein kinase and nuclear factor κβ (NF-κβ) (Abraham and Cho, 
2009). In IBD, there is increased expression of NOD2 on Paneth cells, resulting in 
dysregulated inflammatory cytokine expression and impaired activation of NF-κB, 
ultimately decreasing AMP secretion and contributing to a pro-inflammatory state. 
(Bonen et al. 2003; Lala et al. 2003; Tan et al. 2015).  
The altered microbial composition of the gut in IBD is well studied. The term 
used to characterize a shift in the normal levels of representative microbiota is dysbiosis. 
The dysbiosis and pro-inflammatory state in IBD are related. However, it is unclear if the 
dysbiosis in IBD is a direct cause of inflammation or a reflection of the inflammatory 
processes inherent to the disease pathology (Carding et al. 2015). The general changes in 
the composition of the gut microbiota are well documented (Frank et al. 2007). Some 
studies have aimed to identify select species responsible for the induction of IBD, 
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however, there has been no conclusive evidence supporting a causal relationship between 
a singular species and IBD pathogenesis (Darfeuille-Michaud et al. 2004; Rosenfeld and 
Bressler, 2010). Interestingly, the loss of a several key species appears to influence the 
disease. For example, a reduction in the abundance Faecalibacterium prausnitzii has 
been implicated in enhancing inflammation in IBD as these bacteria demonstrate anti-
inflammatory effects in vitro and in vivo (Packey and Sartor, 2009; Qiu et al. 2013). 
Collectively, the changes in the gut environment that result from the dysbiosis contribute 
to the pathogenic inflammation seen in IBD.  
Figure 9. The intestinal epithelium in inflammatory bowel disease 
Genetics, gut microbiota, and imbalanced inflammatory response disrupt homeostasis at 
the intestinal epithelium. This results in mucosal inflammation and tissue damage. 
Adapted from Coskun, 2014.  
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1.6 CDI and the Gut Microbiome  
Clostridium difficile infection (CDI) is a major health care concern as it represents 
10-35% of all antibiotic-induced diarrheal illness, costs the United States an estimated 
$3.2 billion dollars in health care spending, and kills close to 14,000 people a year 
(Ricciardi et al. 2007; O’Brien et al. 2007; Centers for Disease Control and Prevention 
2013). Since its pathogenic role was discovered in 1978, CDI has been the leading cause 
of nosocomial-related diarrhea (Bartlett, 2006). CDI is primarily a nosocomial disease 
with 80% of its cases starting in a hospital or long-term care facility setting (Khan and 
Elzouki 2014). Because of its increased incidence, severity of disease, and poor 
outcomes, CDI has gained interest from the scientific community (Kuijper et al. 2006). 
As a result, since 2003, there has been a 3-fold increase in number of published articles 
studying C. difficile (Le Monnier et al. 2014).  
C. difficile is a Gram-positive spore-forming anaerobe that infects the colon of 
mammals, causing illness ranging in severity from mild diarrhea to fulminant colitis 
(Kutty et al. 2010). However, C. difficile is considered to be a normal member of the gut 
microbiota (Bien et al. 2013). In a healthy gut, colonization resistance from the resident 
microbial community prevents colonization of C. difficile (Figure 10) (Pechine et al. 
2007). However, following short-term changes in the microbial diversity and distribution 
of the gut, C. difficile is able to colonize the gut readily (De La Cochetiere et al. 2008). 
Pathogenesis of CDI is initiated after ingestion and germination of C. difficile spores 
(Rupnik et al. 2009). The germination process is not well understood and the current 
knowledge of the process is based on studies of other Clostridial species (Edwards and 
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McBride, 2014). Following germination, vegetative C. difficile cells release exotoxins A 
and B, which cause the symptoms of CDI by inducing a pro-inflammatory state and 
disrupting the integrity of the intestinal epithelium (Voth and Ballard, 2005; Kelly and 
Kyne, 2011). The pro-inflammatory state ultimately causes migration of neutrophils to 
the affected site, leading to pseudomembrane colitis, the hallmark characteristic of CDI 
(Bobak et al. 2008). 
 
Figure 10. Proposed mechanism of the colonization resistance imparted by the gut 
microbiota  
(Left) Microbial metabolites and host factors inhibit the germination and growth of C. 
difficile. A healthy and diverse community of gut microbiota also competes for resources, 
limiting the growth of C. difficile. The normal gut microbiota also modulates 
inflammatory responses of the host tissue and stimulates IgA and AMP secretion. (Right) 
Perturbation of the normal gut microbiota caused by antibiotics or other factors alters 
metabolite production and host factor secretion, facilitating the germination of C. difficile 
spores. The dysbiotic state in combination with toxin release by vegetative C. difficile 
alters the immune response of the gut, promoting a pro-inflammatory state and resulting 
in damage to the epithelium. Adapted from Seekatz and Young, 2014.  
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There are many factors linked to the development of CDI (Table 2). These risk 
factors facilitate the pathogenesis of C. difficile by increasing exposure to spores or 
altering the composition of the gut microbiota. For example, the 3 primary risk factors for 
developing CDI are recent hospitalization, advanced age, and antibiotic usage within the 
previous 3 months (Stanley and Burns, 2010). Although these risk factors are found in a 
majority of CDI cases, they are not mandatory in the induction of disease. For example, 
roughly 60% of IBD patients diagnosed with CDI are treated with antibiotics preceding 
diagnosis (Issa et al. 2007). This suggests that the development of CDI typically involves 
a combination of factors and not a singular entity.  
 
Table 2. Risk factors for Clostridium difficile infections 
Adapted from Stanley et al. 2013. 
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SPECIFIC AIMS 
 
As IBD is a risk factor for the development of CDI, the increased incidence of 
CDI in the IBD population is well documented (Issa et al. 2007; Bossuyt et al. 2009; 
Goodhand et al. 2011). Disruption of the gut microbiota clearly plays a role in altering 
the gut environment of IBD patients. However, it is unclear to how this dysbiosis 
influences susceptibility to CDI. This study aims to highlight the GI features of IBD that 
result from its dysbiosis, and how these features facilitate colonization by C. difficile and 
symptom development. 
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PUBLISHED STUDIES 
2.0 Dysbiosis in IBD 
In general, the dysbiosis associated with IBD is defined by an overall decrease in 
diversity of microbial species within the gut, correlating with a decrease in number of 
non-redundant bacterial genes as well (Ott et al. 2004; Frank et al. 2007). There has been 
a multitude of studies analyzing the gut microbiota of IBD patients (Table 3) (Seksik et 
al. 2003; Ott et al. 2004; Swidsinski et al. 2005; Scanlan et al. 2006; Bibiloni et al 2006; 
Manichanh et al. 2006; Gophna et al. 2006; Sepehri et al. 2007; Frank et al. 2007; Wang 
et al. 2007; Dicksved et al. 2008; Takaishi et al. 2008; Swidsinski et al. 2008; Sokol et al. 
2008; Willing et al. 2009; Andoh et al. 2009; Fyderek et al. 2009; Nishikawa et al. 2009; 
Willing et al. 2010; Verma et al. 2010; Schweitz et al. 2010; Kang et al. 2010; Noor et al. 
2010; Frank et al. 2011; Andoh et al. 2011; Walker et al. 2011; Joossens et al. 2011; 
Lepage et al. 2011; Thomazini et al. 2011). In general, alterations of the gut microbiota in 
IBD include abnormal patterns of Clostridial groups, increases in Escherichia coli and 
members of the Bacteroidetes phylum, and decreases in members of the Firmicutes 
phylum (Sokol et al. 2006; Takaishi et al. 2008; Chassaing and Darfeuille-Michaud 2011; 
Walker et al. 2011). However, there are differences in the diversity and microbiology 
between CD and UC. For example, CD-specific shifts in the gut microbiota consist of 
increases in Ruminococcus and Enterobacteriaceae, with decreases in Faecalibacterium 
and Roseburia (Manichanh et al. 2006; Willing et al. 2009; Willing et al. 2010; Kang et 
al. 2010; Walker et al. 2011). On the other hand, UC-specific shifts in the microbiota 
include increases in species from the Prevotellaceae family, Actinobacteria, and 
Proteobacteria (Lepage et al. 2011). 
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Table 3 (continued). Documented microbial alterations in IBD. Adapted from 
Nagalingam and Lynch, 2012. 
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Table 3. Documented microbial alterations in IBD  
é Increase in bacteria compared to healthy controls. ê Decrease in bacteria compared to 
healthy controls. UC, ulcerative colitis; CD, Crohn’s disease; qPCR, quantitative PCR; 
Cl, clones; FISH, fluorescent in situ hybridization; Pyro, 454 pyrosequencing; DGGE, 
denaturing gradient gel electrophoresis; TGGE, temperature gradient gel electrophoresis; 
T-RFLP, terminal restriction fragment length polymorphism; ARISA, automated 
ribosomal spacer analysis; PMA, phylogenetic microarray. Adapted from Nagalingam 
and Lynch, 2012. 
The loss of particular bacteria in the gut of IBD patients has profound effects on 
the gut environment and host. 16S rRNA analysis of fecal samples demonstrates a 
reduction of Clostridial cluster XIVa in IBD (Frank et al. 2007). Species of this cluster 
are from Clostridium, Ruminicoccous, Eubacterium, Coprococcus, Dorea, Lachnospira, 
Roseburia, and Butyrivibrio genera (Collins et al. 1994). However, this cluster does not 
include the pathobiont species Clostridium difficile, which is delegated to Cluster XI 
(Bien et al. 2013). Clostridial species are some of the first bacteria to colonize the gut 
during development (Roberts et al. 1992). In adulthood, Clostridial clusters XIVa 
predominates in the colon, roughly comprising 10-40% of the total bacteria in the gut 
microbiota (Hold et al. 2002; Frank et al. 2007; Manson et al. 2008). Given the presence 
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of Clostridial cluster XIVa early in life and its large abundance in the adult colon, these 
bacteria likely play a crucial role in shaping the gut microbiome (Lopetuso et al. 2013).  
2.1 Clostridial Cluster XIVa Functions in the Colon  
Clostridia colonize specific areas of the colonic mucosa. Using high-power 
magnification and laser capture microdissection, bacteria from Clostridial cluster XIVa 
were found to densely populate areas between the mucosal folds in the colons of mice 
(Nava et al. 2011). The plica semilunaris is an anatomical structure of the human colon 
that is analogous to the mucosal folds observed in mice (Nava et al. 2011). This suggests 
that members of Clostridial cluster XIVa occupy a specific region of the colonic mucosa, 
close to the host epithelium, where they influence a variety of physiological and 
biochemical processes (Lopetuso et al. 2013).  
Clostridial cluster XIVa participates in a variety of functions that help maintain 
gut homeostasis (Figure 11). As Clostridia colonize in close proximity to the gut 
epithelium, this suggests they strongly influence the host immune system (Lopetuso et al. 
2013). These bacteria have been shown to promote the development of αβ T-cell receptor 
intraepithelial lymphocytes and (IgA)-producing cells in the large intestine (Umesaki et 
al. 1999). Additionally, Clostridial cluster XIVa have been shown to induce the 
differentiation of Tregs in the colon and promote increased expression of anti-
inflammatory mediators such as IL-10, matrix metalloproteinases, TGF-β, and 
indoleamine 2,3- dioxygenase (D’Angelo et al. 2001; Atarashi et al. 2011). Interestingly, 
Clostridial cluster XIVa has also been implicated in generating free catecholamines, 
suggesting their role in systemic and local processes influenced by nervous system such 
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as cognition, mood, immune reactions, motility, and water reabsorption in the colon 
(Barry et al. 1994; Barry et al. 1995; Eisenhofer et al. 2004; Sarkar et al. 2010; Nakano et 
al. 2011; Asano et al. 2012).   
 
Figure 11. Regulation of gut homeostasis by Clostridial cluster XIVa 
Clostridial species occupy the interfolds of the colon in close proximity to the epithelial 
surface. They promote the development of αβ T-cell receptor intraepithelial lymphocytes 
and IgA-producing cells through the induction of IL-6, IL-7 and TGF- β. They are also 
able to induce colonic T regulatory cell (Treg) accumulation through the activation of 
Dendritic cells (DCs) and the induction of indoleamine 2,3-dioxygenase (IDO), matrix 
metalloproteinases (MMPs) and TGF-β in colonic epithelial cells. Butyrate produced by 
Clostridial species provides energy to colonocytes and inhibits the activation of NF-kβ, 
providing anti-inflammatory effect. Increased production of IL-10 in Treg cells also 
contribute to anti-inflammatory effects. Finally, Clostridia, enriched in β-glucuronidase 
activity, could be responsible for generating free catecholamines, including 
norepinephrine (NE) and dopamine (DA). Adapted from Lopetuso et al. 2013.  
 
2.2 Clostridial cluster XIVa and Loss of Colonization Resistance 
As a part of their role in maintaining gut homeostasis, bacteria from Clostridial 
cluster XIVa also contribute to the colonization resistance of the gut. In general, the loss 
	   33	  
of colonization resistance to C. difficile is attributable to the decreased diversity of the gut 
microbiota. Several mechanisms describe how the normal gut microbiota provide 
resistance to C. difficile such as competition for nutrients, ecological competition, and 
niche exclusion (Britton and Young, 2012). While many factors have been identified as 
disruptors of the gut microbiota (Table 2), antibiotic therapy is most commonly 
associated with the development of CDI (Seekatz and Young, 2014). Antibiotic-induced 
perturbation of the gut microbiota can be detected within a few days of usage, though 
long-term effects of these drugs are also demonstrated (Detlefsen et al. 2008; 
Antonopoulos et al. 2009). The effects of antibiotics vary depending on the type of 
antibiotic used and the composition of gut microbiota prior to administration (Table 4) 
(Antonopoulos et al. 2009).  
16S rRNA analysis and metagenomic sequencing demonstrated a reduction of 
Clostridial cluster XIVa in the feces of CDI patients, suggesting that the loss of these 
bacteria plays a role in development of CDI (Perez-Cobas et al. 2014). Additionally, 
since depletion of Clostridial cluster XIVa is also a characteristic of IBD-associated 
dysbiosis, it is likely that this loss contributes to the susceptibility IBD patients have 
towards developing CDI (Frank et al 2007). To understand how the loss of Clostridial 
cluster XIVa governs this susceptibility, factors such as bile acid metabolism and 
butyrate fermentation are considered as these two metabolic processes are modified by 
Clostridial cluster XIVa and demonstrate inhibitor effects towards C. difficile (Smith et 
al. 2013; Buffie et al. 2014) 
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Table 4. Changes in the gut microbiota by different types of antibiotics identified by 
16S rRNA analysis   
Adapted from Lankelma et al. 2015.    
 
2.3 Bile Acid Metabolism 
 The gut microbiota plays an important role in the metabolism of bile acids. Bile 
acids are saturated/hydroxylated C-24 cyclopentanephenanthrene sterols that are 
produced from cholesterol in the liver. Bile acids are conjugated with amino acids 
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(typically taurine or glycine) in the liver to form bile salts, which are secreted into the 
lumen of the small intestine to aid in digestion and absorption of dietary lipids. After 
passing through the small intestine, colonic bacteria modify bile salts by deconjugating 
and dehydroxylating the sterols in order to promote passive reabsorption along the 
ascending colon (Figure 12) (Ridlon et al. 2006). Deconjugation occurs when the amide 
bond between the bile salt and amino acid is hydrolyzed by bile salt hydrolases (BSHs), 
enzymes produced by colonic bacteria. Dehydroxylation, on the other hand, is a complex 
process that is carried out by enzymes named hydroxysteroid dehydrogenases, encoded 
by the bile acid-inducible (bai) operon (Ridlon et al. 2006).  
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Figure 12. Bacteria biotransformation of bile salts in the colon 
Hydroxy carbons of cholic acid are labeled. Dehydroxylation of cholic acid (CA) at 
carbons 3,7, or 12 produce various secondary bile acids. BSH, bile salt hydrolase; HSDH, 
hydroxysteroid dehydrogenase. Adapted from Ridlon et al. 2006.  
 
In vitro studies have demonstrated the effects bile acids exert on C. difficile 
(Wilson, 1983; Sorg and Sonenshein, 2008). The growth of vegetative C. difficile is 
inhibited by bile acids such as chenodeoxycholate (CDCA) (Figure 13) (Wilson, 1983; 
Sorg and Sonenshein, 2008). However, other bile acids such as cholic acid (CA), as well 
as the conjugated bile salt taurocholate and the free amino acid glycine, stimulate the 
germination of C. difficile spores (Sorg and Sonenshein, 2008; Ridlon et al. 2006). 
Interestingly, deoxycholic acid (DCA) both inhibits the growth of vegetative C. difficile 
and stimulates the germination of C. difficile spores (Sorg and Sonenshein, 2008). This 
suggests that the positive and negative effects exerted by bile acids on C. difficile depend 
on the composition of the bile acids along the GI tract.  
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Bile acid composition differs in the gall bladder and feces (Figure 14) (Ridlon et 
al. 2006). Major alterations of the bile acid composition occur in the distal ileum and 
colon where 95% of bile acids are reabsorbed and subjected to dehydroxylating activity 
of colonic bacteria, respectively (Ridlon et al. 2006). As the composition of bile acids 
differ in the different segments of the GI tract, the germinating and inhibiting effects of 
bile acids must also vary. For example, in the small intestines CA is the most abundant 
bile acid, suggesting that C. difficile spores are largely germinated in this area (Thomas et 
al. 2001; Sorg and Sonenshein, 2008). However, in the colon, DCA is the predominate 
Figure 13. Bile acid metabolism and C. 
difficile 
Conjugated bile salts produced by the liver 
are metabolized in the intestine, primarily 
by activities carried out by members of the 
gut microbiota. Primary bile salts as well as 
their metabolites can have direct effects on 
C. difficile, primarily affecting germination 
of spores as well as the activity of 
vegetative cells. Adapted from Britton and 
Young, 2012. 	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bile acid and largely restricts the growth of any vegetative C. difficile (Ridlon et al. 2006; 
Sorg and Sonenshein, 2008). This suggests that even though spores may germinate in the 
small intestine due to effects of CA, any vegetative C. difficile that arises in the colon is 
unable to grow due to DCA. The balance between CA and DCA is critical in the 
germination and inhibition of C. difficile. Thus, the bacteria that carry out the conversion 
of CA into DCA play a crucial role in providing the inhibitory effects imparted by DCA.  
 
Members of Clostridial cluster XIVa demonstrate 7α-dehydroxylating activity 
and are capable of converting CA into DCA (Ridlon et al. 2006; Kang et al. 2008). Buffie 
et al. 2014 demonstrated the bile acid-mediated effects of Clostridial cluster XIVa in 
vivo. In their study, rats were challenged with C. difficile spores following antibiotic 
administration (Buffie et al. 2014). 16S rRNA analysis of feces from CDI-susceptible and 
Figure 14. Bile acid composition in the 
gall bladder and feces 
“Other” bile acids refer to oxo- and 3b- 
hydroxy derivatives of secondary bile 
acids. CDCA, chenodeoxycholic acid; 
DCA, deoxycholic acid; LCA, lithocholic 
acid; UDCA, ursodeoxycholic acid. 
Adapted from Ridlon et al. 2006.  
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CDI-resistant rats identified 11 bacterial species that conferred resistance to CDI. The 11 
species comprised a small portion of the overall microbial composition (6%), but were 
predominantly members of Clostridial cluster XIVa (Buffie et al. 2014). Clostridium 
scindens (member of Clostridial cluster XIVa), the species that conferred the strongest 
resistance to CDI, was then transferred into CDI-susceptible rats, which decreased C. 
difficile content in feces and increased survival rate, confirming the CDI-resistance of C. 
scindens. To test the mechanism of resistance of C. scindens, secondary bile acid content 
was measured in the feces of CDI-susceptible and CDI-resistant rats and was 
significantly increased in the latter (Buffie et al. 2014). PCR-based assay for 7α-
hydroxysteroid dehydrogenase (encoded for by the bai operon) correlated C. scindens 
with the increased secondary bile acid content and CDI-resistance (Buffie et al. 2014).  
To extend their study to humans, Buffie and colleagues analyzed the microbiota 
obtained from feces of patients undergoing allogeneic hematopoietic stem-cell 
transplantation (allo-HSCT), a cohort recently given antibiotics as a prophylactic measure 
(Buffie et al. 2014). Of the 24 allo-HSCT patients, 12 were diagnosed with CDI and the 
other 12 were carriers of C. difficile without clinical diagnosis of CDI. By comparing the 
species that demonstrated strong inhibition against C. difficile in both experiments, C. 
scindens was identified as conferring resistance in both humans and rats, corroborating 
their rodent-based correlation analysis (Buffie et al. 2014).  
2.4 Metabolite Imbalance 
 In addition to metabolism of bile acids, members of gut microbiota also 
participate in fermentation of short chain fatty acids (SCFAs). SCFAs are the products of 
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bacterial fermentation of indigestible dietary fiber and primarily include propionate, 
acetate, and butyrate (Figure 15) (Cummings 1983; Mortensen and Nordgaard-Andersen 
1993; Cummings et al. 1996). These metabolites have different effects on the host. For 
example, propionate and acetate are mostly absorbed into the bloodstream and exert their 
effects systemically, whereas butyrate is the primary energy source of colonocytes and 
exerts local effects in the gut (Topping and Clifton 2001; Maslowski et al. 2009; Smith et 
al. 2013). As many bacteria in Clostridial cluster XIVa are butyrogenic, the loss of these 
species as seen in IBD, negatively affects the butyrate concentrations in the gut (Clausen 
and Mortensen 1995; Den Hond et al. 1998; Bien et al. 2013; Smith et al. 2013). The 
depletion of butyrate alters the host in several ways and ultimately weakens the host’s 
colonization resistance and ability to tolerate the toxin-mediated effects of C. difficile.  
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Figure 15. Schematic of the gut microbiota involved in the metabolism of short 
chain fatty acids  
Acetate and lactate are intermediates, but also exist as end products. The phyla 
represented in the figure are limited to cultured species. CH4, methane; SO4, sulfate; 
H2S, hydrogen disulfide; CoA, coenzyme A. Adapted from Knudsen, 2015.  
 
 Butyrate contributes to the host’s colonization resistance by altering the pH of the 
luminal contents. Given the pKa of butyrate (~4.8) and luminal pH of the colon (5.6 in 
the proximal colon and 6.3 in the distal colon), approximately 90% of the butyrate in the 
colon exists in its dissociable anionic form (Cummings et al. 1987; Velazquez et al. 
1997). The ionized butyrate lowers the pH of the colon, which is shown to inhibit the 
growth and toxin production of vegetative C. difficile (May et al. 1994; Wong et al. 
2006). However, the lowered pH also decreases the solubility of free bile acids and 
denatures 7α-hydroxysteroid dehydrogenase (Thorton, 1981). This effectively prevents 
formation of secondary bile acids such as DCA, which ironically also weakens the 
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colonization resistance to C. difficile for reasons discussed above. While the lowered pH 
appears to have contrasting effects on colonization resistance, the result of this 
antagonistic relationship is unclear.    
 In addition to altering the pH, the decreased butyrate in the colon also weakens 
the colonization resistance against C. difficile by weakening the barrier defense imparted 
by the mucus layer. As discussed above, the mucus layer is the first line defense against 
the bacteria living in the lumen of the intestines. In comparison to non-IBD controls, IBD 
patients have a thinner mucus layer that is more permeable to colonic bacteria (Pullan et 
al. 1994; Einerhand et al. 2002; Fyderek et al. 2009; Swidsinski et al. 2007). From in 
vitro and ex vivo studies, butyrate is known to stimulate MUC2 production, suggesting 
that the decrease in butyrate observed in IBD contributes to the thinner mucus layer and 
weakened barrier defense (Finnie et al. 1995; Willemsen et al. 2003; Augenlicht et al. 
2003; Gaudier et al. 2004; Hatayama et al. 2007). Additionally, the thinner mucus layer 
has recently been shown to inflict negative affects on the gut’s adaptive immune system. 
In a study by Olson and colleagues, the mucus layer was shown to work synergistically 
with IgA in preventing epithelial injury due to C. difficile toxins by protecting IgA from 
proteolytic cleavage, thus conserving its structural integrity and function (Olson et al. 
2013). Although IgA is somewhat resistant to cleavage in the GI environment, these 
results suggest that IgA in the colon of IBD patients is more prone to cleavage due to the 
thinned mucus layer. The increased cleavage of IgA ultimately dampens the adaptive 
immune system’s ability to opsonize vegetative C. difficile and its toxins, resulting in 
increased susceptibility to toxin-mediated inflammation.  
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 As a result of decreased butyrate fermentation, AMP secretion is also altered in 
the gut of IBD patients. LL-37 is a type of AMP (cathelicidin) secreted by colonic 
epithelial and macrophages (Bals, 2000). While LL-37 has demonstrated antibacterial 
effects against Gram-negative bacteria, it also has been shown to have anti-inflammatory 
effects (Bowdish et al. 2006; Gombart et al. 2009). In a study by Hing et al. 2013, 
exogenous LL-37 decreased tissue damage and inflammation in C. difficile colitis in 
mice. The authors demonstrated that the reduced inflammation was the result of 
decreased secretion of tumor necrosis factor- α (TNF-α), a pro-inflammatory cytokine 
released in response to C. difficile toxin (Rocha et al. 1997; Pothoulakis and Lamont, 
2001; Hing et al. 2013;). As in vitro studies have demonstrated that butyrate stimulates 
the expression of LL-37 in colonic epithelial cells, it is suggested that the decreased 
butyrate also limits the expression of LL-37 in the gut (Schauber et al. 2003). 
Collectively, this indicates that patients with IBD are less able to control the toxin-
mediated inflammation associated with CDI, making them more susceptible to symptom 
development.  
DISCUSSION 	   The current review highlights evidence that suggests the decreased abundance of 
Clostridial cluster XIVa in the gut microbiota of IBD confers susceptibility to developing 
CDI by promoting colonization by C. difficile and perpetuating its toxin-mediated 
inflammation. Given the multifactorial etiology of IBD and CDI, it is difficult to fully 
assess how the loss of Clostridial cluster XIVa affects bile acid metabolism and butyrate 
fermentation. Complicating this notion is the fact that other bacteria in the gut, such as 
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Bacteroidetes species, carry out both bile acid metabolism and butyrate fermentation 
(McFarlane and McFarlane, 2003; Ridlon et al. 2006; Antharam et al. 2013). 
Additionally, as Clostridial cluster XIVa influences many cellular and biochemical 
processes in the gut, the loss of this taxa likely alters multiple other factors, thus further 
complicating how bile acid metabolism and butyrate fermentation are ultimately affected 
in vivo. However, in describing how Clostridial cluster XIVa provides colonization 
resistance to C. difficile, it is clear that the gut microbiota have profound effects on its 
host, both physiologically and biochemically. Also, there is corroborating evidence that 
the loss Clostridial cluster XIVa facilitates C. difficile pathogenesis. As noted above, 
advanced age (>65 years old) is one of the primary risk factors for CDI (Stanley and 
Burns, 2010) As the gut microbiota of elderly individuals is marked by a decrease in 
Clostridial cluster XIVa, this suggests that increased incidence of CDI in the elderly may 
be due to a similar mechanism as discussed previously (Figure 7) (Claesson et al. 2011).  
The loss of Clostridial cluster XIVa observed in IBD and CDI provides a targeted 
approach in curing these diseases. Recently, fecal microbiota transplantation (FMT) has 
emerged as a treatment that restores the normal diversity and abundance of the gut 
microbiota. FMT has demonstrated great success in treating recurrent CDI as a 
systematic review discovered 89% (246/275) of patients diagnosed with recurrent CDI 
had no relapse of disease after undergoing FMT (Brandt and Reddy, 2011). However, the 
success of FMT in treating IBD has demonstrated mixed results (Damman et al. 2012). In 
knowing that the colonization resistance to C. difficile is positively influenced by 
members of Clostridial cluster XIVa, donor stool to be used in FMT should be screened 
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for inclusion of species from this taxa in order to assure efficacy. This may also improve 
the efficacy of FMT in treatment of IBD as restoration of the normal abundance and 
diversity of Clostridial cluster XIVa would likely restore the anti-inflammatory effects 
imparted by these bacteria (D’Angelo et al. 2001; Atarashi et al. 2011).  
 The loss of Clostridial cluster XIVa observed in IBD exerts strong local effects in 
the gut environment, though systemic effects may also exist. For example, Clostridial 
species have recently been implicated in the production of free catecholamines (Asano et 
al. 2012). In this study, gnotobiotic mice that were associated with 46 different 
Clostridial species, including members from cluster XIVa, demonstrated significantly 
higher levels of norepinephrine and dopamine in the lumen of the gut in comparison to 
germ-free mice (Asano et al. 2012). From this, it is suggested that the Clostridial species 
containing β-glucuronidase activity increase the luminal concentrations of norepinephrine 
and dopamine by converting these products from their biologically inactive, glucoronide-
conjugated form (Asano et al. 2012). As the gut is densely innervated with noradrenergic 
and dopaminergic neurons, the loss of Clostridial bacteria would have detrimental effects 
on the brain-gut axis due to decreases in luminal catecholamines (Li et al. 2006; Asano et 
al. 2012). However, there is still much to learn regarding this mechanism and its effects 
on the host (Lopetuso et al. 2013). 
 Interestingly, the findings of this review contradict data reporting IBD as a risk 
factor for colorectal cancer. Colorectal cancer is thought to evolve in IBD from the 
recurrent/chronic inflammation and ulceration of host tissue (Jawad et al. 2011). Due to 
its hydrophobicity, DCA is able to passively diffuse across cell membranes and activate 
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signaling pathways, ultimately inducing cancer formation by exerting selective pressure 
for the generation of apoptosis-resistant epithelial cells (Qiao et al. 2001; Rao et al. 2002; 
Im and Martinez, 2004; Bernstein et al. 2005). However, due to decreased accumulation 
of DCA that results from the loss of 7α-dehydroxylating activity, it should be expected 
that IBD patients would exhibit a decreased risk of colorectal cancer. While this appears 
to contradict evidence supporting the increased risk of colorectal cancer in IBD, there are 
still many uncertainties involving this mechanism. However, this finding has large 
implications as recently, it was suggested that the risk of colorectal cancer in the 
population is much lower than previously thought (Kassem et al. 2014).     
 As Clostridial cluster XIVa demonstrates protective effects against C. difficile, 
further understanding of how these species are altered will provide insight into the role 
that the gut microbiota plays in CDI and IBD. However, there has been a lack studies 
capable of assessing the physiology of these bacteria in vivo. One reason for this is that 
molecular techniques used to study microbial communities are ill equipped for the task. 
For example, while 16S rRNA analysis and metagenomic sequencing enable scientists to 
determine the structure and functional capacity of microbial communities, these 
techniques provide little information regarding which species of bacteria are active, 
damaged, or responsive to a given compound in these environments (Maurice et al. 
2013). This suggests that studies should combine sequencing methods with flow 
cytometry and fluorescence-activated cell sorting, as these single-cell methods have been 
used to characterize the physiological structure of environmental and host-associated 
microbial communities in the past (Joux and Lebaron, 2000; Shapiro, 2000; Ben-Amor et 
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al. 2005). In a study using such methods, Maurice and colleagues demonstrated that the 
physiological responses of the gut microbiota to antibiotics varied between individuals, 
over time, and with the type of drug (Maurice et al. 2013). In knowing how the 
physiology of the gut microbiota differs from person to person, medicine can take a 
personalized approach, thus increasing the efficacy of treatments and limiting adverse 
events such as unexplained drug toxicity (Maurice et al. 2013).  
 Though many details are yet to be discovered, it is clear that the gut microbiome 
has a major influence on host physiology. As there are a variety of diseases linked to the 
gut microbiome such as IBD, CDI, colorectal cancer, irritable bowel syndrome, obesity, 
diabetes, allergies, rheumatoid arthritis, Parkinson’s disease, and multiple sclerosis, 
understanding how short-/long-term effects influence the function and shape of the gut 
microbiota will advance medicine (Backhed et al. 2004; Frank et al. 2007; De La 
Cochetiere et al. 2008; Jawad et al. 2011; Kverka and Tlaskalova-Hogenova, 2013; 
Crouzet et al. 2013; Abrahamsson et al. 2014; Hu et al. 2015). With continued research of 
the gut microbiota and its relationship with the human host, more will be understood of 
its role in human disease. 
CONCLUSION 
The funding of major projects such as the HMP has initiated a new era in human 
medicine. Not only are researchers discovering more about the roles bacteria have in 
disease, but also how these same bacteria actually promote, and are essential for, human 
health. The amount of research that has been conducted on the human microbiome is 
significant. From the collected data, it is clear that body habitats, such as the human gut, 
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are highly complex. The interactions between the host and microbes are pertinent in 
maintaining homeostasis within such environments. In the case of IBD, disruption of this 
homeostasis is detrimental and facilitates complications such as unwanted inflammation 
and susceptibility to infections such as CDI. With the rising prevalence of IBD and CDI, 
continued research into the gut microbiome is necessary. From this, novel therapies that 
manipulate the gut microbiota will hopefully improve diagnosis and treatment of such 
diseases.   
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